Detalhe da pesquisa
1.
Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
Bioorg Chem
; 142: 106950, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37924753
2.
Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.
Biochem Biophys Res Commun
; 623: 17-22, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35868068
3.
Y06014 is a selective BET inhibitor for the treatment of prostate cancer.
Acta Pharmacol Sin
; 42(12): 2120-2131, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33654218
4.
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity.
J Med Chem
; 67(9): 6952-6986, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649304
5.
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
J Med Chem
; 65(1): 785-810, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34962793
6.
Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.
Eur J Med Chem
; 236: 114311, 2022 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385803